MedTrace Logo

A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer

NCT00383266 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2016-01-11

Study results available
· View outcomes & findings →

Summary

This is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.

Conditions

  • Esophageal Neoplasms

Interventions

DRUG

Pemetrexed

DRUG

Carboplatin

Sponsors & Collaborators

Principal Investigators

  • Maria Q. Baggstrom, M.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-11-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383266 on ClinicalTrials.gov